Recently, Hong Kong has been hit by the epidemic continuously. On February 16, Kang Keren, senior vice president of Wondfo Biotech, said that in response to the epidemic in Hong Kong, Wondfo's "Anti-epidemic pioneer" is preparing to go to the front line and guarantee supply.

CACLP Booth Number：A4-0501

As one of the leading China POCT companies, Wondfo's COVID-19 (2019-nCoV) antibody test kit (colloidal gold method) and COVID-19 (2019-nCoV) antigen test kit (colloidal gold method) are both the first approved rapid tests for COVID-19 in China. Among them, the COVID-19 (2019-nCoV) antigen test is simple and easy to operate. It can realize point-of-care test without relying on equipment, and get results within 15-20 minutes.

At present, Wondfo has developed a variety of fast, accurate and easy-to-use tests, which can provide "nucleic acid PCR + antigen + antibody" three-in-one solution. The solution can meet the different application scenarios of COVID-19 rapid test, which will greatly help Hong Kong fight the epidemic.

Kang Keren said that since the outbreak of the epidemic, Wondfo has took multiple measures to allocate resources and increase production capacity. Wondfo has provided support for global epidemic prevention and control. "In response to the epidemic in Hong Kong, we will use our resources to meet Hong Kong's urgency, fully support it, and stand ready to support the forefront of the fight against the epidemic."

At present, Wondfo's "Anti-epidemic pioneer" has completed preparations and is ready to go to the front line to provide support for Hongkong. According to reports, the "Anti-epidemic pioneer" has participated in the anti-epidemic for many times with rich experience.

It is worth noting that Wondfo is currently assisting the Second People's Hospital of Guangdong Province to carry out the pilot work of the rapid test and application of COVID-19 antigen. The digital-intelligent prevention and control solution for COVID-19 antigen test launched by Wondfo has been applied in the prevention and control of closed and controlled areas, international shipping, and international imports. At the same time, the company's rapid antigen test has played an important role in emergency many times. The relevant mature experience can be applied to Hong Kong this time, providing support for improving the efficiency of epidemic prevention.